Target intelligence / Profile preview

F-box protein 25 (FBXO25)

Target
FBXO25
Molecular classification
F-box protein, Component of the SCF (SKP1-cullin-F-box) E3 ubiquitin ligase complex, E3 ubiquitin ligase, Protein coding gene
01

Overview

F-box protein 25 (FBXO25) is a nuclear E3 ubiquitin ligase belonging to the F-box protein family, specifically the Fbxs class. It functions as the substrate-recognition component of the SCF (SKP1-CUL1-F-box protein) E3 ligase complex, mediating phosphorylation-dependent ubiquitination of target proteins for proteasomal degradation. FBXO25 is enriched in unique nuclear compartments called FBXO25-associated nuclear domains (FANDs), which are dynamic and influenced by transcriptional activity. It is broadly expressed, most strongly in the central nervous system, with proposed roles in protein quality control and regulation of nuclear protein aggregation—especially in preventing aggregation of pathogenic polyglutamine-containing proteins such as mutant huntingtin. Gene variants and altered expression have been associated with several disease states, including neurodegenerative disease, cancer, inflammation, immunological disorders, and certain developmental disorders[1][2][3][5].

Other names
F-box only protein 25FBXO25FBX25F-box protein Fbx25
02

Mechanism of action

Recruitment of substrates to the SCF E3 ubiquitin ligase complex for ubiquitination and subsequent proteasomal degradation Regulation of nuclear protein aggregation (notably polyglutamine-containing huntingtin)

03

Biological functions

Ubiquitin-protein transferase activitySubstrate recognition component of SCF-type E3 ligase complexProtein ubiquitinationNegative regulation of protein aggregationActin bindingNuclear compartment organization
04

Disease associations

Cancer (association proposed)Inflammation (association proposed)Neurodegenerative disease (prevention of huntingtin protein/aggregation, possibly relevant to Huntington’s disease)Immunoglobulin disordersAutism spectrum disorder (gene variant linked)Genetically inherited cerebral disorder
05

Safety considerations

Potential challenges relate to undesired alteration of protein degradation and nuclear protein aggregation if therapeutically modulated (inferred from its role in ubiquitination and protein quality control)[2][5].

Beyond the preview

Go deeper on F-box protein 25 (FBXO25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box protein 25 (FBXO25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call